STOCK TITAN

Carlyle-linked entities report 691,735 shares in Q32 Bio (QTTB)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Q32 Bio Inc. Schedule 13G/A shows that a group of Carlyle-related entities reports shared beneficial ownership of 691,735 shares of Common Stock, representing 4.1% of the class as of June 18, 2026. The filing cites 16,956,415 shares outstanding as disclosed in the issuer's Form 10-Q filed May 5, 2026. The reporting chain traces record ownership to Abingworth Bioventures VII LP with investment/dispositive authority delegated to Abingworth LLP; multiple Carlyle entities disclaim direct beneficial ownership while the cover pages report shared voting and dispositive power.

Positive

  • None.

Negative

  • None.

Insights

Large investment firms report a passive, sub-5% stake in Q32 Bio.

The filing lists 691,735 shares (4.1%) beneficially owned as of June 18, 2026, based on 16,956,415 shares outstanding. Ownership is reported through a nested Carlyle/Abingworth structure with shared voting and dispositive power indicated.

Because the position is under 5% and filed on Schedule 13G/A, it is presented as passive ownership. Subsequent filings would show any change in status or percentage.

Complex entity chain yields shared control disclosures rather than direct ownership claims.

The statement discloses delegated investment and dispositive authority from Abingworth Bioventures VII LP to Abingworth LLP and lists multiple Carlyle affiliates as reporting persons sharing power over the same 691,735 shares.

Signatures by authorized signatories are included; follow-on Schedule 13D/G amendments would be required if the holder moves from passive to active intent.

Beneficial ownership 691,735 shares Beneficially owned as of June 18, 2026
Percent of class 4.1% Calculated from outstanding shares disclosed in issuer Form 10-Q
Shares outstanding 16,956,415 shares Issuer's Form 10-Q filed May 5, 2026 (used as denominator)
beneficial ownership regulatory
"The information contained on the cover pages to this is incorporated by reference"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared dispositive power regulatory
"Shared power to dispose or to direct the disposition of: 691,735"
Schedule 13G/A regulatory
"Item 1. (a) Name of issuer: Q32 Bio Inc."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Carlyle report in QTTB (Q32 Bio) in this filing?

The filing reports shared beneficial ownership of 691,735 shares, equal to 4.1% of the class as of June 18, 2026. That percentage is calculated using 16,956,415 shares outstanding cited from the issuer's Form 10-Q filed May 5, 2026.

Who is the record holder of the shares reported in the QTTB filing?

The filing states that Abingworth Bioventures VII LP is the record holder of the reported shares. Investment and dispositive power over those shares is delegated to Abingworth LLP, which is reflected in the shared power disclosures.

Does the Schedule 13G/A indicate active control or passive ownership for QTTB?

This Schedule 13G/A presents the position as passive ownership under Section 13(g) conventions. The report lists shared voting and dispositive power but does not assert an intent to influence control; a conversion to an active stance would require an amended filing.

How was the 4.1% ownership percentage in QTTB calculated?

The percentage is shown as 4.1% based on 691,735 shares beneficially owned divided by the issuer's disclosed 16,956,415 shares outstanding as reported in the issuer's Form 10-Q filed May 5, 2026.

Which entities signed the QTTB Schedule 13G/A on behalf of the reporting group?

Authorized signatories include Anne K. Frederick and Emma O'Reilly signing for multiple Carlyle and Abingworth entities. The filing includes a Joint Filing Agreement (Exhibit 99) referenced as previously filed.





746964105

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: Limited Liability Company


SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: Limited Liability Company


SCHEDULE 13G




Comment for Type of Reporting Person: Limited Liability Company


SCHEDULE 13G




Comment for Type of Reporting Person: Limited Liability Company


SCHEDULE 13G




Comment for Type of Reporting Person: Limited Liability Company


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



The Carlyle Group Inc.
Signature:/s/ Anne K. Frederick
Name/Title:Anne K. Frederick, Corporate Secretary
Date:07/06/2026
Carlyle Holdings I GP Inc.
Signature:/s/ Anne K. Frederick
Name/Title:Anne K. Frederick, Managing Director
Date:07/06/2026
Carlyle Holdings I GP Sub L.L.C.
Signature:By: Carlyle Holdings I GP Inc., its sole member, /s/ Anne K. Frederick
Name/Title:Anne K. Frederick, Managing Director
Date:07/06/2026
Carlyle Holdings I L.P.
Signature:/s/ Anne K. Frederick
Name/Title:Anne K. Frederick, Managing Director
Date:07/06/2026
CG Subsidiary Holdings L.L.C.
Signature:/s/ Anne K. Frederick
Name/Title:Anne K. Frederick, Managing Director
Date:07/06/2026
TC Group, L.L.C.
Signature:/s/ Anne K. Frederick
Name/Title:Anne K. Frederick, Managing Director
Date:07/06/2026
Carlyle Investment Management L.L.C.
Signature:/s/ Anne K. Frederick
Name/Title:Anne K. Frederick, Managing Director
Date:07/06/2026
Carlyle Genesis UK LLC
Signature:By: Carlyle Investment Management L.L.C., its sole member, /s/ Anne K. Frederick
Name/Title:Anne K. Frederick, Managing Director
Date:07/06/2026
Abingworth LLP
Signature:/s/ Emma O'Reilly
Name/Title:Emma O'Reilly. Authorized Signatory
Date:07/06/2026
Abingworth Bioventures VII LP
Signature:/s/ Emma O'Reilly
Name/Title:Emma O'Reilly. Authorized Signatory
Date:07/06/2026
Exhibit Information

Exhibit 99: Joint Filing Agreement (previously filed)